FRANKLIN LAKES, N.J., July 31, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014, representing an increase of 5.1 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.
"We are pleased with our solid third quarter results, with each of our segments contributing to growth," said Vincent A. Forlenza, Chairman, CEO and President. "Our consistent performance demonstrates that our strategy remains sound in this dynamic healthcare environment."
Third Quarter and Nine-Month Fiscal 2014 Operating Results
Reported diluted earnings per share from continuing operations for the third quarter were $1.65 compared with $1.47 in the prior-year period, representing a 12.2 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the third quarter increased by 10.9 percent. Current quarter results include a pre-tax charge within R&D of $9 million, or $0.03 diluted earnings per share from continuing operations, relating to program asset write-offs and obligations. Results from the prior-year period included a charge of $22 million, or $0.07 per share from continuing operations, associated with an antitrust class action settlement. Excluding the impact of these items, adjusted diluted earnings per share from continuing operations were $1.68 compared with $1.54 in the prior-year period. This represents an increase of 9.1 percent, or 7.8 percent on a currency-neutral basis.
For the nine-month period ending June 30, 2014, diluted earnings per share from continuing operations were $4.47, compared with $4.21 in the prior-year period. This represents growth of 6.2 percent, or 10.0 percent on a currency-neutral basis. Excluding the current quarter charge associated with the R&D program termination and the antitrust class action settlement charge in the prior year's quarter, as well as other items detailed in the accompanying reconciliation of non-GAAP financial measures, adjusted diluted earnings per share from continuing operations for the nine-month period ending June 30, 2014 were $4.57 compared with $4.28 in the prior-year period. This represents an increase of 6.8 percent, or 10.5 percent on a currency-neutral basis. Excluding the first quarter incremental impact of the medical device excise tax, which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act, adjusted diluted earnings per share from continuing operations were $4.62 compared with $4.28 in the prior-year period. This represents growth of 7.9 percent, or 11.7 percent on a currency-neutral basis.
Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.201 billion, representing an increase of 5.3 percent compared with the prior-year period, or an increase of 4.7 percent on a foreign currency-neutral basis. The segment's revenue growth was primarily driven by strong sales in Medical Surgical Systems. For the nine-month period ended June 30, 2014, BD Medical revenues increased 6.1 percent, or 6.4 percent on a currency-neutral basis.
In the BD Diagnostics segment, worldwide revenues for the quarter were $679 million, representing an increase of 3.7 percent on both a reported and foreign currency-neutral basis compared with the prior-year period. Strong growth in the Preanalytical Systems unit were partially offset by ongoing softness in Women's Health and Cancer in the U.S. For the nine-month period ended June 30, 2014, BD Diagnostics revenues increased 2.0 percent, or 3.0 percent on a currency-neutral basis.
In the BD Biosciences segment, worldwide revenues for the quarter were $277 million, representing an increase of 7.7 percent compared with the prior-year period, or an increase of 6.6 percent on a foreign currency-neutral basis. The segment's growth was driven by solid instrument placements and a favorable comparison to the prior year. For the nine-month period ended June 30, 2014, BD Biosciences revenues increased 7.1 percent, or 7.6 percent on a currency-neutral basis.
Geographic Results
Third quarter revenues in the U.S. of $871 million represent an increase of 2.8 percent over the prior-year period. Revenues outside of the U.S. were $1.286 billion, representing an increase of 6.7 percent compared with the prior-year period, or an increase of 6.0 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products.
For the nine-month period ended June 30, 2014, revenues in the U.S. were $2.546 billion, representing an increase of 1.8 percent compared with the prior-year period. Revenues outside of the U.S. were $3.698 billion, representing an increase of 7.1 percent when compared with the prior-year period, or 8.1 percent on a foreign currency-neutral basis.
Fiscal 2014 Outlook for Full Year
The Company reaffirms its previously communicated currency-neutral revenue guidance range of 4.5 to 5.0 percent. On a reported basis, the Company expects revenue growth of 4.0 to 4.5 percent. The Company is also reaffirming its previous guidance for diluted earnings per share from continuing operations for the full fiscal year to be between $6.22 and $6.25 excluding the impact of the previously aforementioned adjustments. On a reported basis, earnings per share for the full fiscal year 2014 are expected to be between $6.12 and $6.15. This represents growth of 7.0 to 7.5 percent over 2013 adjusted diluted earnings per share of $5.81. On a foreign currency-neutral basis, adjusted diluted earnings per share growth is expected to be between 10.0 to 10.5 percent, or 11.0 to 11.5 percent excluding the incremental impact of the medical device tax. The Company plans to complete the repurchase, subject to market conditions, of $450 million of its common stock for fiscal year 2014.
Conference Call Information
A conference call regarding BD's third quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday, July 31, 2014. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Thursday, August 7(th), 2014, confirmation number 69111053.
Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.
About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit
www.bd.com
.
This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in millions, except share and per share
data)
Three Months Ended June 30,
2014 2013 % Change
---- ---- --------
REVENUES $2,157 $2,053 5.1
Cost of products sold 1,046 993 5.4
Selling and administrative 528 534 (1.2)
Research and development 137 121 13.5
------------------------ --- --- ----
TOTAL OPERATING COSTS
AND EXPENSES 1,712 1,648 3.9
------------ ----- ----- ---
OPERATING INCOME 445 405 10.1
Interest income 12 6 99.3
Interest expense (33) (35) (5.6)
Other (expense) income, net (2) 3 NM
--------------------------- --- --- ---
INCOME FROM CONTINUING OPERATIONS
BEFORE
INCOME TAXES 423 379 11.6
Income tax provision 97 87 11.5
-------------------- --- --- ----
INCOME FROM CONTINUING OPERATIONS 326 292 11.6
INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$0 AND $6, RESPECTIVELY - 10 NM
----------------------- --- --- ---
NET INCOME $326 $302 8.1
---------- ---- ---- ---
EARNINGS PER SHARE
Basic:
Income from continuing
operations $1.69 $1.50 12.7
Income from discontinued
operations $ - $0.05 NM
Net income $1.69 $1.55 9.0
Diluted:
Income from continuing
operations $1.65 $1.47 12.2
Income from discontinued
operations $ - $0.05 NM
Net income $1.65 $1.52 8.6
AVERAGE SHARES OUTSTANDING (in
thousands)
Basic 193,054 194,879
Diluted 197,005 198,719
------- ------- -------
NM - Not Meaningful
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in millions, except share and per share
data)
Nine Months Ended June 30,
2014 2013 % Change
---- ---- --------
REVENUES $6,244 $5,953 4.9
Cost of products sold 3,045 2,869 6.1
Selling and administrative 1,584 1,545 2.5
Research and development 410 362 13.4
------------------------ --- --- ----
TOTAL OPERATING COSTS
AND EXPENSES 5,039 4,775 5.5
------------ ----- ----- ---
OPERATING INCOME 1,204 1,178 2.3
Interest income 36 26 38.7
Interest expense (99) (104) (4.9)
Other income, net 4 6 (33.4)
----------------- --- --- -----
INCOME FROM CONTINUING OPERATIONS
BEFORE
INCOME TAXES 1,145 1,105 3.6
Income tax provision 261 267 (2.3)
-------------------- --- --- ----
INCOME FROM CONTINUING OPERATIONS 884 838 5.5
INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$0 AND $222, RESPECTIVELY - 364 NM
------------------------- --- --- ---
NET INCOME $884 $1,203 (26.5)
---------- ---- ------ -----
EARNINGS PER SHARE
Basic:
Income from continuing
operations $4.57 $4.29 6.5
Income from discontinued
operations $ - $1.87 NM
Net income $4.57 $6.16 (25.8)
Diluted:
Income from continuing
operations $4.47 $4.21 6.2
Income from discontinued
operations $ - $1.83 NM
Net income $4.47 $6.04 (26.0)
AVERAGE SHARES OUTSTANDING (in
thousands)
Basic 193,624 195,312
Diluted 197,813 199,111
------- ------- -------
NM - Not Meaningful
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in millions)
Three Months Ended June 30,
2014 2013 % Change
---- ---- --------
BD MEDICAL
----------
United States $468 $449 4.4
International 733 692 5.9
------------- --- ---
TOTAL $1,201 $1,140 5.3
----- ------ ------ ---
BD DIAGNOSTICS
--------------
United States $310 $310 (0.2)
International 370 345 7.2
------------- --- ---
TOTAL $679 $655 3.7
----- ---- ---- ---
BD BIOSCIENCES
--------------
United States $93 $89 5.1
International 184 168 9.1
------------- --- ---
TOTAL $277 $257 7.7
----- ---- ---- ---
TOTAL REVENUES
--------------
United States $871 $848 2.8
International 1,286 1,205 6.7
------------- ----- -----
TOTAL $2,157 $2,053 5.1
----- ------ ------ ---
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in millions)
Nine Months Ended June 30,
2014 2013 % Change
---- ---- --------
BD MEDICAL
----------
United States $1,344 $1,287 4.4
International 2,037 1,899 7.2
------------- ----- -----
TOTAL $3,381 $3,186 6.1
----- ------ ------ ---
BD DIAGNOSTICS
--------------
United States $932 $953 (2.2)
International 1,073 1,013 5.9
------------- ----- -----
TOTAL $2,005 $1,966 2.0
----- ------ ------ ---
BD BIOSCIENCES
--------------
United States $270 $262 3.2
International 588 540 9.0
------------- --- ---
TOTAL $858 $801 7.1
----- ---- ---- ---
TOTAL REVENUES
--------------
United States $2,546 $2,501 1.8
International 3,698 3,452 7.1
------------- ----- -----
TOTAL $6,244 $5,953 4.9
----- ------ ------ ---
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in millions)
United States
-------------
2014 2013 % Change
---- ---- --------
BD MEDICAL
----------
Medical Surgical Systems $256 $246 4.3
Diabetes Care 118 117 0.9
Pharmaceutical Systems 94 86 9.2
TOTAL $468 $449 4.4
----- ---- ---- ---
BD DIAGNOSTICS
--------------
Preanalytical Systems $172 $167 3.0
Diagnostic Systems 137 143 (4.0)
------------------ --- ---
TOTAL $310 $310 (0.2)
----- ---- ---- ----
BD BIOSCIENCES $93 $89 5.1
-------------- --- --- ---
TOTAL UNITED STATES $871 $848 2.8
------------------- ---- ---- ---
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in millions)
International
-------------
% Change
--------
2014 2013 Reported FXN FX Impact
---- ---- -------- --- ---------
BD MEDICAL
----------
Medical Surgical Systems $333 $315 5.8 7.3 (1.5)
Diabetes Care 140 133 5.8 6.0 (0.2)
Pharmaceutical Systems 259 244 6.2 1.3 4.9
---
TOTAL $733 $692 5.9 5.0 0.9
----- ---- ---- --- --- ---
BD DIAGNOSTICS
--------------
Preanalytical Systems $192 $178 8.0 8.6 (0.6)
Diagnostic Systems 178 167 6.4 6.0 0.4
------------------
TOTAL $370 $345 7.2 7.3 (0.1)
----- ---- ---- --- --- ----
BD BIOSCIENCES $184 $168 9.1 7.4 1.7
-------------- ---- ---- --- --- ---
TOTAL INTERNATIONAL $1,286 $1,205 6.7 6.0 0.7
------------------- ------ ------ --- --- ---
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in millions)
Total
-----
% Change
--------
2014 2013 Reported FXN FX Impact
---- ---- -------- --- ---------
BD MEDICAL
----------
Medical Surgical Systems $590 $561 5.1 6.0 (0.9)
Diabetes Care 258 250 3.5 3.6 (0.1)
Pharmaceutical Systems 353 330 6.9 3.4 3.5
TOTAL $1,201 $1,140 5.3 4.7 0.6
----- ------ ------ --- --- ---
BD DIAGNOSTICS
--------------
Preanalytical Systems $364 $345 5.6 5.9 (0.3)
Diagnostic Systems 315 310 1.6 1.4 0.2
------------------
TOTAL $679 $655 3.7 3.7 -
----- ---- ---- --- --- ---
BD BIOSCIENCES $277 $257 7.7 6.6 1.1
-------------- ---- ---- --- --- ---
TOTAL REVENUES $2,157 $2,053 5.1 4.6 0.5
-------------- ------ ------ --- --- ---
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in millions)
United States
-------------
2014 2013 % Change
---- ---- --------
BD MEDICAL
----------
Medical Surgical Systems $759 $731 3.9
Diabetes Care 358 336 6.4
Pharmaceutical Systems 227 220 3.4
TOTAL $1,344 $1,287 4.4
----- ------ ------ ---
BD DIAGNOSTICS
--------------
Preanalytical Systems $507 $496 2.1
Diagnostic Systems 425 457 (7.0)
------------------ --- ---
TOTAL $932 $953 (2.2)
----- ---- ---- ----
BD BIOSCIENCES $270 $262 3.2
-------------- ---- ---- ---
TOTAL UNITED STATES $2,546 $2,501 1.8
------------------- ------ ------ ---
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in millions)
International
-------------
% Change
--------
2014 2013 Reported FXN FX Impact
---- ---- -------- --- ---------
BD MEDICAL
----------
Medical Surgical Systems $961 $905 6.2 8.6 (2.4)
Diabetes Care 415 388 6.9 9.3 (2.4)
Pharmaceutical Systems 661 606 9.1 5.6 3.5
TOTAL $2,037 $1,899 7.2 7.8 (0.6)
----- ------ ------ --- --- ----
BD DIAGNOSTICS
--------------
Preanalytical Systems $547 $513 6.5 8.3 (1.8)
Diagnostic Systems 526 499 5.3 7.3 (2.0)
------------------
TOTAL $1,073 $1,013 5.9 7.8 (1.9)
----- ------ ------ --- --- ----
BD BIOSCIENCES $588 $540 9.0 9.6 (0.6)
-------------- ---- ---- --- --- ----
TOTAL INTERNATIONAL $3,698 $3,452 7.1 8.1 (1.0)
------------------- ------ ------ --- --- ----
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in millions)
Total
-----
% Change
--------
2014 2013 Reported FXN FX Impact
---- ---- -------- --- ---------
BD MEDICAL
----------
Medical Surgical Systems $1,720 $1,635 5.1 6.5 (1.4)
Diabetes Care 773 725 6.7 7.9 (1.2)
Pharmaceutical Systems 888 826 7.5 5.0 2.5
TOTAL $3,381 $3,186 6.1 6.4 (0.3)
----- ------ ------ --- --- ----
BD DIAGNOSTICS
--------------
Preanalytical Systems $1,054 $1,010 4.4 5.3 (0.9)
Diagnostic Systems 951 956 (0.6) 0.5 (1.1)
------------------
TOTAL $2,005 $1,966 2.0 3.0 (1.0)
----- ------ ------ --- --- ----
BD BIOSCIENCES $858 $801 7.1 7.6 (0.5)
-------------- ---- ---- --- --- ----
TOTAL REVENUES $6,244 $5,953 4.9 5.4 (0.5)
-------------- ------ ------ --- --- ----
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in millions)
Three Months Ended June 30,
---------------------------
% Change
--------
2014 2013 Reported FXN FX Impact
---- ---- -------- --- ---------
TOTAL SAFETY REVENUES
---------------------
United States $304 $301 1.2 1.2 -
International 265 237 11.6 12.4 (0.8)
------------- --- --- ---- ----
TOTAL $569 $538 5.8 6.1 (0.3)
----- ---- ---- --- --- ----
BY SEGMENT
----------
BD Medical $284 $268 6.1 6.6 (0.5)
BD Diagnostics 285 270 5.5 5.7 (0.2)
-------------- --- --- --- ----
TOTAL $569 $538 5.8 6.1 (0.3)
----- ---- ---- --- --- ----
Nine Months Ended June 30,
--------------------------
% Change
--------
2014 2013 Reported FXN FX Impact
---- ---- -------- --- ---------
TOTAL SAFETY REVENUES
---------------------
United States $906 $879 3.1 3.1 -
International 751 685 9.7 11.9 (2.2)
------------- --- --- --- ----
TOTAL $1,657 $1,564 6.0 6.9 (0.9)
----- ------ ------ --- --- ----
BY SEGMENT
----------
BD Medical $832 $776 7.2 8.3 (1.1)
BD Diagnostics 825 788 4.7 5.6 (0.9)
-------------- --- --- --- ----
TOTAL $1,657 $1,564 6.0 6.9 (0.9)
----- ------ ------ --- --- ----
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures
(Unaudited)
Three Months Ended June 30,
---------------------------
2014 2013 Growth Foreign Foreign
Currency Currency
Translation Neutral
Change Growth % Foreign
Currency
Neutral
Growth %
-------
Reported Diluted Earnings per Share from Continuing Operations $1.65 $1.47 $0.18 $0.02 $0.16 12.2% 10.9%
Charge associated with the decision to terminate a research and 0.03 -
development program in the Medical segment; the charge relates
to program asset write-offs and obligations ($9 million or $6 million after-tax)
Charge associated with the litigation settlement related to indirect purchaser antitrust class action cases ($22 million or $14 million after-tax) - 0.07
Adjusted Diluted Earnings per Share from Continuing Operations $1.68 $1.54 $0.14 $0.02 $0.12 9.1% 7.8%
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2014 Year-to-Date Reconciliation of Non-GAAP Financial Measures
(Unaudited)
Nine Months Ended June 30,
--------------------------
2014 2013 Growth Foreign Currency Translation Foreign Currency Neutral
Change Growth % Foreign
Currency
Neutral
Growth %
-------
Reported Diluted Earnings per Share from Continuing Operations $4.47 $4.21 $0.26 $(0.16) $0.42 6.2% 10.0%
Write-off of capitalized product software and, to a lesser extent, 0.06 -
fixed assets primarily resulting from the discontinuance of an
instrument product development program in the Biosciences
segment ($20 million or $12 million after-tax)
Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment ($11 million or $8
million after-tax) 0.04 -
Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership ($8 million or $5 million
after-tax) (0.03) -
Charge associated with the decision to terminate a research and development program in the Medical segment; the charge relates to
program asset write-offs and obligations ($9 million or $6 million after-tax) 0.03 -
Charge associated with the litigation settlement related to indirect purchaser antitrust class action cases ($22 million or $14
million after-tax) - 0.07
Adjusted Diluted Earnings per Share from Continuing Operations $4.57 $4.28 $0.29 $(0.16) $0.45 6.8% 10.5%
The incremental impact in first quarter fiscal year 2014 of the medical device excise tax which went into effect in January 2013 under
the U.S. Patient Protection and Affordable Care Act ($14 million or $9 million after-tax) 0.05 -
Adjusted Diluted Earnings per Share from Continuing Operations without incremental first quarter fiscal year 2014 impact
of Medical Device Excise Tax $4.62 $4.28 $0.34 $(0.16) $0.50 7.9% 11.7%
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2014 Outlook Reconciliation
Reported
Basis FX Impact FXN Basis
----- --------- ---------
Revenues - Full Year 2014 estimated growth 4.0% - 4.5% (0.5%) 4.5% - 5.0%
Full Year Full Year
2014 2013 % Increase
---- ---- ----------
(estimated)
Reported Fully Diluted Earnings per Share
from Continuing Operations $ 6.12 - 6.15 $4.67 NM
Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the
Biosciences segment 0.06
Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment 0.04
Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership (0.03)
Charge associated with the decision to terminate a research and development program in the Medical segment; the charge relates to program asset write-offs and obligations 0.03
Charge associated with the litigation settlement related to indirect purchaser antitrust class action cases 0.07
Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI 1.06
Non-cash pension settlement charge associated with lump sum 0.02
benefit payments made from the Company's U.S. supplemental
pension plan, as such payments exceeded the service and
interest components of the plan's pension cost for the year. The
charge also included settlement losses associated with certain
foreign pension plans
Adjusted Fully Diluted Earnings per Share
from Continuing Operations $ 6.22 - 6.25 $5.81 7.0% - 7.5%
===
FX Impact (3.0%)
Adjusted FXN Growth 10.0% - 10.5%
Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and
Affordable Care Act) (1.0%)
Adjusted FXN Growth (excluding the medical device excise tax) 11.0% - 11.5%
NM - Not Meaningful
FXN = Foreign Currency Neutral
Contact:
Monique N. Dolecki, Investor Relations - 201-847-5453
Alyssa J. Zeff, Corporate Communications - 201-847-4358
SOURCE BD (Becton, Dickinson and Company)